Porgaviximab

DB17773ExperimentalProtein Based Therapies

Porgaviximab: Overview.

Mechanism
Curator reviewed
Also known as
IMMUNOGLOBULIN G1-KAPPA, ANTI-(EBOLAVIRUS GLYCOPROTEIN) CHIMERIC HOMO SAPIENS-MUS MUSCULUS MONOCLONAL ANTIBODY: .GAMMA.1 HEAVY CHAIN (1-451) (MUS MUSCULUS VH (IGHV6-6*02 (95%) (IGHD)-IGHJ4*01 (94%)) (8.10.12) (1-121) -HOMO SAPIENS IGHG1*01(CH1 K97>R(218) · Immunoglobulin g1, anti-(ebolavirus glycoprotein) (human-mus musculus monoclonal c2g4 heavy chain), disulfide with human-mus musculus monoclonal c2g4 .kappa.-chain, dimer · Zmap component c2g4 · Zmapp component c2g4
Code names
2G4 · C2G4

Resolves to

Compound
UNII07EY0HWO2MCAS1792982-55-8
Targets
Q05320GP

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Porgaviximab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In